Morgan Stanley Rates Evommune (EVMN) buy, $26 Price Target

Morgan Stanley maintains its buy rating for Evommune, Inc. with a $26 price target, a 95.64% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 9:03 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Morgan Stanley rated Evommune, Inc. ($EVMN) "buy" with a $26 price target on June 30, 2026.

Since the rating, $EVMN is up 0.4% after 1 week, down 14.6% after 1 month and down 61.1% to date (from the $13.29 close on Jun 30, 2026).

EVMN Evommune, Inc.

$5.17 -70.13% year to date

Daily close · Oct 16, 2026

Key Points

Morgan Stanley reiterated its buy rating on Evommune, Inc. (NYSE:EVMN) with a $26 target price on June 30, 2026.
Morgan Stanley's $26 price target implies 95.64% upside from Evommune, Inc.'s ($EVMN) current $13.29 share price.
Evommune, Inc., a biotech firm focusing on chronic inflammatory diseases, traded near $15.05 on Tuesday with a market cap of approximately $906.9 million.
Institutional investors like RA Capital Management and RTW Investments are increasing their stakes in Evommune, Inc., while analysts maintain strong buy ratings.

Get $EVMN trade alerts by text

We text you when insiders, Congress or big funds trade $EVMN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Evommune, Inc. alert may contain errors. Disclosures

Morgan Stanley reiterated its buy rating on Evommune, Inc. (NYSE:EVMN) on June 30, 2026. The firm set a price target of $26 for the biotechnology company. This update reflects Morgan Stanley's continued confidence in Evommune's potential.

Analyst rating track record

Morgan Stanley vs. the S&P 500

YTD return +40.81% hypothetical

All-time return +37.14% S&P 500 +34.03%

vs. S&P 500 +3.11% ahead of the index

Hypothetical returns from Morgan Stanley's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

On June 30, 2026, Morgan Stanley maintained its buy rating on Evommune, Inc. with a price target of $26. This follows a series of positive analyst actions, including HC Wainwright & Co.'s reiterated buy rating with a $50 target on May 26, 2026. RBC Capital also reiterated a buy rating with a $48 target on April 10, 2026. The consensus among analysts is a strong buy, with a mean target price of $52.25 based on eight opinions.

Evommune, Inc. Stock Up 37.7%

Shares of NYSE:EVMN traded near $15.05 on Tuesday. Evommune, Inc. has a market cap of about $906.9 million. The company isn't currently profitable, so it doesn't have a meaningful P/E ratio. Its 52-week low is $13.89, and its high is $33.20. The stock's 50-day moving average is $23.10, while the 200-day moving average stands at $22.04. Evommune maintains a strong liquidity position with a current ratio of 20.36 and a quick ratio of 19.94.

12-month forecast

$EVMN price target

Evommune, Inc. daily closes and this analyst's $26 target. Not advice.

Other Institutional Activity in Evommune, Inc.

Several institutional investors are active in Evommune, Inc. RA Capital Management, L.P. increased its holdings by 35,868 shares, ending with 3,494,638 shares valued at about $80.3 million. RTW Investments, LP also boosted its stake by 218,564 shares, reaching a total of 1,502,235 shares worth $34.5 million, marking a 17% increase. Meanwhile, JPMorgan Chase & Co raised its position by 150,519 shares, holding 1,459,420 shares valued at $32.1 million, reflecting an 11.5% increase.

About Evommune, Inc.

Evommune, Inc. is a clinical-stage biotechnology company based in Palo Alto, California. It focuses on developing therapies for chronic inflammatory diseases such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Led by CEO Mr. Luis C. Pena, the company employs 48 people and is working on products like EVO756 for treating CSU and AD, and EVO301 for AD and UC.

Bottom Line

Morgan Stanley's reiterated buy rating and $26 price target on Evommune, Inc. underscore the firm's positive outlook on the company's potential. Investors keep a close eye on Evommune due to its focus on innovative treatments for chronic inflammatory diseases. Institutional activity and strong analyst consensus suggest continued interest in the company's future prospects.